Success Metrics

Clinical Success Rate

85.7%

Based on 6 completed trials

Completion Rate

86%(6/7)

Active Trials

1(11%)

Results Posted

67%(4 trials)

Terminated

1(11%)

Phase Distribution

Ph phase_3

33%

Ph phase_1

33%

Ph phase_2

11%

Ph not_applicable

11%

Ph phase_4

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

3(33.3%)

Phase 2Efficacy & side effects

1(11.1%)

Phase 3Large-scale testing

3(33.3%)

Phase 4Post-market surveillance

1(11.1%)

N/ANon-phased studies

1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(6)

Terminated(1)

Other(1)

Detailed Status

Completed6

Recruiting1

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

85.7%

Most Advanced

Phase 4

Trials by Phase

Phase 13 (33.3%)

Phase 21 (11.1%)

Phase 33 (33.3%)

Phase 41 (11.1%)

N/A1 (11.1%)

Trials by Status

completed667%

recruiting111%

terminated111%

unknown111%

Recent Activity

1 active trials

Showing 5 of 9

completedphase_3

A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT07155668

recruitingphase_1

A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants

NCT07635095

completedphase_1

Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab

NCT05339100

unknownnot_applicable

Assessment of Injectable Medication Platforms

NCT05367531

completedphase_3

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

NCT03875508

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT07155668Phase 3

A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Completed

NCT07635095Phase 1

A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants

Recruiting

NCT05339100Phase 1

Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab

Completed

NCT05367531Not Applicable

Assessment of Injectable Medication Platforms

Unknown

NCT03875508Phase 3

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Completed

NCT02750930Phase 4

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

Terminated

NCT02722044Phase 3

Usability of an AI for M923 in Subjects With Moderate to Severe RA

Completed

NCT03193957Phase 2

An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis

Completed

NCT01087944Phase 1

A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C

Completed

All 9 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 9